Status: Recruiting
CUE-102 in Recurrent Glioblastoma
The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)
Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: David Reardon, MDUpdated: Mar 5, 2026Locations: 2
Eligibility criteria
Have HLA-A*0201 genotype as determined by genomic testing performed locally; [+51]
Received any therapy for tumor recurrence other than surgery; [+34]